Skip to main
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is a strong buy due to its promising pipeline of investigational gene therapy treatments, positive results in recent clinical trials, and expected regulatory approvals in the near future. The company's cash runway is also expected to last into early 2027, providing financial stability. However, risks to price target achievement include potential failures in clinical trials and competition in the market. With an estimated market value of $1.64B, analysts have a price target of $26 per share, indicating a strong upside potential.

Bears say

Regenxbio is a clinical-stage biotechnology company with a 12-month price target of $26 per share and a total estimated market value of $1.64B. However, there are significant risks associated with this valuation, including the possibility of unsuccessful clinical trials, failure to secure regulatory approval, and potential challenges in achieving commercial success. Additionally, potential dilution risk could also impact the price target.

REGENXBIO (RGNX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 10 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.